Table 1.
Summary of the CD8 T cell responses to the Sp17 peptides by DLBCL patients.
| Patients | Diagnosis | HLA status | Pattern of Sp17 staining | γ-IFN response to peptides per 50,000 cells | |||||
|---|---|---|---|---|---|---|---|---|---|
| Sp17(1) | Sp17(2) | Sp17(3) | No peptide | HIV-1 | PHA | ||||
| Significant response | |||||||||
| 1 | DLBCL(dn) | A∗0201+ | Cytoplasm and <10% nuclei | 84 ± 12 | 46 ± 10 | 24 ± 6 | 12 ± 2 | 18 ± 4 | 126 ± 28 |
| 2 | DLBCL(dn) | A∗0201+ | Scattered nuclei | 58 ± 10 | 74 ± 14 | 30 ± 8 | 18 ± 4 | 20 ± 4 | 94 ± 16 |
| 5 | DLBCL(dn) | A∗0201+ | — | 48 ± 4 | 34 ± 16 | 30 ± 8 | 16 ± 4 | 20 ± 4 | 104 ± 18 |
| 7 | DLBCL(dn) | A∗0101+ | <10% nuclei | 16 ± 4 | 14 ± 2 | 48 ± 6 | 12 ± 2 | 10 ± 2 | 124 ± 16 |
| 8 | DLBCL(dn) | A∗0201+ | ND | 102 ± 16 | 24 ± 4 | 32 ± 8 | 20 ± 4 | 16 ± 4 | 204 ± 24 |
| 9 | DLBCL(dn) | A∗0201+ | — | 86 ± 12 | 40 ± 8 | 38 ± 10 | 12 ± 4 | 20 ± 4 | 128 ± 18 |
| 12 | DLBCL(dn) | A∗0201+ | Weak cytoplasm and < 5% nuclei | 98 ± 14 | 76 ± 14 | 42 ± 6 | 22 ± 2 | 16 ± 4 | 154 ± 16 |
| 14 | DLBCL(dn) | A∗0201+ | ND | 66 ± 6 | 44 ± 8 | 26 ± 6 | 12 ± 6 | 14 ± 2 | 84 ± 14 |
| 18 | DLBCL(dn) | A∗0201+ | Weak cytoplasm and <5% nuclei | 68 ± 12 | 54 ± 4 | 30 ± 8 | 18 ± 4 | 20 ± 2 | 94 ± 16 |
| 19 | DLBCL(t) | A∗0201+ | <10% nuclei | 56 ± 10 | 62 ± 14 | 22 ± 4 | 20 ± 2 | 18 ± 4 | 86 ± 12 |
| 21 | DLBCL(dn) | A∗0201+ | Cytoplasm + scattered < 5% nuclei | 46 ± 4 | 14 ± 2 | 30 ± 8 | 12 ± 0 | 16 ± 2 | 110 ± 12 |
| 22 | DLBCL(t) | A∗0201+ | ND | 86 ± 8 | 64 ± 14 | 40 ± 8 | 20 ± 4 | 10 ± 1 | 88 ± 10 |
| 37 | DLBCL(dn) | A∗0101+ | <5% nuclei | 38 ± 4 | 24 ± 14 | 32 ± 4 | 12 ± 2 | 6 ± 1 | 178 ± 8 |
| 39 | T cell rich | A∗0201+ | — | 28 ± 2 | 12 ± 2 | 22 ± 4 | 10 ± 2 | 6 ± 1 | 108 ± 10 |
| No significant response | |||||||||
| 3 | DLBCL(dn) | A∗0201+ | — | 28 ± 8 | 42 ± 6 | 28 ± 4 | 16 ± 8 | 20 ± 4 | 88 ± 22 |
| 4 | DLBCL(dn) | A∗0201+ | — | 40 ± 6 | 38 ± 12 | 22 ± 4 | 20 ± 4 | 16 ± 6 | 132 ± 18 |
| 6 | DLBCL(dn) | A∗0201+ | — | 10 ± 2 | 12 ± 4 | 20 ± 2 | 12 ± 6 | 6 ± 2 | 148 ± 10 |
| 10 | DLBCL(dn) | A∗0101+ | ND | 24 ± 4 | 26 ± 2 | 16 ± 2 | 18 ± 2 | 12 ± 6 | 106 ± 18 |
| 11 | DLBCL(dn) | A∗0201+ | ND | 36 ± 10 | 22 ± 4 | 20 ± 8 | 18 ± 6 | 22 ± 4 | 112 ± 10 |
| 13 | DLBCL(dn) | A∗0201+ | — | 32 ± 8 | 24 ± 4 | 18 ± 8 | 12 ± 6 | 16 ± 4 | 98 ± 12 |
| 15 | DLBCL(dn) | A∗0101+ | ND | 16 ± 2 | 20 ± 6 | 28 ± 8 | 10 ± 6 | 6 ± 2 | 86 ± 10 |
| 16 | DLBCL(dn) | A∗0201+ | — | 36 ± 6 | 32 ± 8 | 30 ± 8 | 12 ± 6 | 20 ± 10 | 94 ± 16 |
| 17 | DLBCL(dn) | A∗0201+ | ND | 16 ± 1 | 14 ± 2 | 22 ± 2 | 16 ± 2 | 10 ± 4 | 114 ± 10 |
| 20 | DLBCL(dn) | A∗0101+ | Cytoplasm + scattered < 5% nuclei | 32 ± 1 | 28 ± 8 | 36 ± 8 | 18 ± 4 | 16 ± 1 | 134 ± 16 |
| 38 | DLBCL(dn) | A∗0201+ | ND | 26 ± 2 | 24 ± 4 | 32 ± 2 | 20 ± 6 | 16 ± 10 | 114 ± 18 |
| 40 | DLBCL(dn) | A∗0201-negative, A∗0101-negative | ND | 16 ± 4 | 14 ± 4 | 26 ± 4 | 14 ± 2 | 10 ± 2 | 64 ± 12 |
| 41 | DLBCL(dn) | A∗0201-negative, A∗0101-negative | — | 18 ± 6 | 20 ± 4 | 12 ± 4 | 10 ± 2 | 8 ± 2 | 66 ± 10 |
| 42 | DLBCL(dn) | A∗0201-negative, A∗0101-negative | ND | 26 ± 4 | 22 ± 6 | 18 ± 6 | 22 ± 4 | 20 ± 2 | 102 ± 16 |
| 43 | DLBCL(dn) | A∗0201-negative, A∗0101-negative | — | 24 ± 10 | 34 ± 14 | 20 ± 8 | 22 ± 4 | 16 ± 2 | >500 |
| 48 | DLBCL(dn) | A∗0201-negative, A∗0101-negative | — | 16 ± 4 | 24 ± 14 | 28 ± 8 | 22 ± 6 | 20 ± 2 | 94 ± 16 |
| 49 | DLBCL(dn) | A∗0201-negative, A∗0101-negative | ND | 24 ± 2 | 18 ± 4 | 22 ± 6 | 14 ± 2 | 10 ± 4 | 144 ± 18 |
| Healthy donors | |||||||||
| 1 | A∗0201+ | ND | 16 ± 4 | 12 ± 4 | 16 ± 4 | 18 ± 4 | 8 ± 2 | 68 ± 12 | |
| 2 | A∗0201+ | ND | 18 ± 2 | 20 ± 2 | 12 ± 4 | 8 ± 4 | 6 ± 2 | 76 ± 10 | |
| 3 | A∗0201+ | ND | 32 ± 4 | 36 ± 4 | 24 ± 6 | 16 ± 4 | 20 ± 2 | 112 ± 18 | |
| 4 | A∗0301+ | ND | 26 ± 10 | 28 ± 8 | 12 ± 2 | 10 ± 4 | 16 ± 2 | 88 ± 14 | |
DLBCL(dn): de novo diffuse large B cell lymphoma; DLBCL(t): diffuse large B cell lymphoma transformed; TCR: T cell rich B cell lymphoma. The results +/− are from triplicate ELISPOT cultures. The SD was calculated using standard techniques. Significant γ-IFN responses are highlighted in bold. ND, not determined.